IL149069A0 - Regulators of the hedgehog pathway, compositions and uses related thereto - Google Patents
Regulators of the hedgehog pathway, compositions and uses related theretoInfo
- Publication number
- IL149069A0 IL149069A0 IL14906900A IL14906900A IL149069A0 IL 149069 A0 IL149069 A0 IL 149069A0 IL 14906900 A IL14906900 A IL 14906900A IL 14906900 A IL14906900 A IL 14906900A IL 149069 A0 IL149069 A0 IL 149069A0
- Authority
- IL
- Israel
- Prior art keywords
- regulators
- compositions
- function
- hedgehog pathway
- uses related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15921599P | 1999-10-13 | 1999-10-13 | |
US22927300P | 2000-08-30 | 2000-08-30 | |
PCT/US2000/028479 WO2001027135A2 (fr) | 1999-10-13 | 2000-10-13 | Regulateurs du signal hedgehog, compositions et utilisations desdits regulateurs |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149069A0 true IL149069A0 (en) | 2002-11-10 |
Family
ID=26855755
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14906900A IL149069A0 (en) | 1999-10-13 | 2000-10-13 | Regulators of the hedgehog pathway, compositions and uses related thereto |
IL149069A IL149069A (en) | 1999-10-13 | 2002-04-10 | Hedgehog route regulators, preparations and their use associated with these regulators |
IL179814A IL179814A (en) | 1999-10-13 | 2006-12-04 | Preparations containing HEDGEHOG route regulators for use in regulating differentiation and proliferation of cells, controlling the growth and development of pancreatic tissue and treating hyperproliferative disorders |
IL213594A IL213594A (en) | 1999-10-13 | 2011-06-16 | Use of a type and rectum alkaloid for in vitro drug preparation and method to inhibit mitotic cell proliferation using this alkaloid |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL149069A IL149069A (en) | 1999-10-13 | 2002-04-10 | Hedgehog route regulators, preparations and their use associated with these regulators |
IL179814A IL179814A (en) | 1999-10-13 | 2006-12-04 | Preparations containing HEDGEHOG route regulators for use in regulating differentiation and proliferation of cells, controlling the growth and development of pancreatic tissue and treating hyperproliferative disorders |
IL213594A IL213594A (en) | 1999-10-13 | 2011-06-16 | Use of a type and rectum alkaloid for in vitro drug preparation and method to inhibit mitotic cell proliferation using this alkaloid |
Country Status (9)
Country | Link |
---|---|
US (5) | US7098196B1 (fr) |
EP (2) | EP1235851B1 (fr) |
JP (2) | JP5420128B2 (fr) |
AT (1) | ATE328002T1 (fr) |
AU (2) | AU781524B2 (fr) |
CA (1) | CA2386190C (fr) |
DE (1) | DE60028411T2 (fr) |
IL (4) | IL149069A0 (fr) |
WO (1) | WO2001027135A2 (fr) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098196B1 (en) | 1999-10-13 | 2006-08-29 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
EP1387674B1 (fr) * | 2000-10-13 | 2017-01-18 | Curis, Inc. | Antagonistes hedgehog, procedes et utilisations associees |
US7708998B2 (en) * | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
WO2002044344A2 (fr) * | 2000-11-28 | 2002-06-06 | Curis, Inc. | Cultures d'epithelioma cutane basocellulaire, compositions et methodes associees |
CA2452152A1 (fr) | 2001-07-02 | 2002-10-10 | Sinan Tas | Utilisation de cyclopamine dans le traitement du psoriasis |
CA2452151C (fr) * | 2001-07-02 | 2012-01-03 | Sinan Tas | Utilisation de cyclopamine, un inducteur de la differenciation et de l'apoptose des cellules du carcinome baso-cellulaire, dans le traitement du carcinome baso-cellulaire et d'autres tumeurs utilisant la voie hedgehog/smoothened aux fins de la proliferation de l'apoptose |
US20080118493A1 (en) * | 2003-07-15 | 2008-05-22 | Beachy Philip A | Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity |
US20070231828A1 (en) * | 2003-10-01 | 2007-10-04 | Johns Hopkins University | Methods of predicting behavior of cancers |
WO2005032343A2 (fr) * | 2003-10-01 | 2005-04-14 | The Johns Hopkins University | Signalisation hedgehog dans la regeneration, la neoplasie et la metastase prostatique |
US20080057071A1 (en) * | 2003-10-20 | 2008-03-06 | Watkins David N | Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer |
CN101044139B (zh) * | 2004-08-27 | 2011-06-08 | 无限药品股份有限公司 | 环杷明类似物及其使用方法 |
WO2006026430A2 (fr) * | 2004-08-27 | 2006-03-09 | Infinity Pharmaceuticals, Inc. | Analogues de cyclopamine et procedes d'utilisation de ceux-ci |
WO2006039569A1 (fr) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Polytherapie d'inhibiteurs hedgehog, de rayonnement et d'agents chimiotherapeutiques |
AU2006246923A1 (en) * | 2005-05-16 | 2006-11-23 | Island Laboratories Inc. | System and method for promoting hair growth and improving hair and scalp health |
US20110034498A1 (en) * | 2006-03-24 | 2011-02-10 | Mcgovern Karen J | Dosing regimens for the treatment of cancer |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
KR20090117956A (ko) * | 2007-03-07 | 2009-11-16 | 인피니티 디스커버리, 인코포레이티드 | 시클로파민 락탐 유사체 및 그의 사용 방법 |
JP2010520295A (ja) * | 2007-03-07 | 2010-06-10 | インフィニティ・ディスカバリー・インコーポレイテッド | へテロ環状シクロパミン類似体及びその使用方法 |
EP2224807B1 (fr) * | 2007-12-27 | 2016-11-09 | Infinity Pharmaceuticals, Inc. | Procédés de réduction stéréosélective |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
CA2710377A1 (fr) * | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Traitements therapeutiques contre le cancer |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009155283A2 (fr) * | 2008-06-17 | 2009-12-23 | Duke University | Dosage radiomarqué de la cyclopamine destiné au récepteur smoothened |
EP2334686B1 (fr) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Analogues de cortistatine et leurs synthèses |
US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
JP2009143963A (ja) * | 2009-03-25 | 2009-07-02 | Sinan Tas | 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ/スムーズンド信号を使用する腫瘍を治療するための製薬組成物 |
WO2010117800A2 (fr) * | 2009-03-30 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Régulation shh et méthodes associées |
FR2948367A1 (fr) | 2009-07-24 | 2011-01-28 | Centre Nat Rech Scient | Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog |
ES2567134T3 (es) | 2009-08-05 | 2016-04-20 | Infinity Pharmaceuticals, Inc. | Transaminación enzimática de análogos de ciclopamina |
CN102711479A (zh) * | 2009-11-06 | 2012-10-03 | 无限药品股份有限公司 | Hedgehog通道抑制剂的口服制剂 |
WO2011088404A1 (fr) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Traitement de pathologies fibrotiques à l'aide d'inhibiteurs de la voie hedgehog |
CA2799579A1 (fr) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Composes chimiques, compositions et procedes pour modulation de kinases |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
FR2967498B1 (fr) | 2010-11-16 | 2015-01-02 | Centre Nat Rech Scient | Utilisation de derives de quinolinone comme outil de recherche |
ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
CA2842190A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
FR2980477B1 (fr) | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2020009849A (es) | 2012-11-01 | 2021-09-13 | Infinity Pharmaceuticals Inc | Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa. |
AU2013352256A1 (en) | 2012-11-29 | 2015-06-18 | Strasspharma, Llc | Methods of modulating follicle stimulating hormone activity |
WO2014151386A1 (fr) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
RU2019134551A (ru) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
JP2014028835A (ja) * | 2013-09-18 | 2014-02-13 | Sinan Tas | 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
BR112016014760A2 (pt) | 2013-12-24 | 2017-12-12 | Harvard College | composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína |
MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
WO2015160986A2 (fr) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
WO2015168079A1 (fr) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k |
WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
WO2016182932A1 (fr) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Analogues de la cortistatine, synthèses, et utilisations de ces derniers |
WO2016196928A1 (fr) | 2015-06-04 | 2016-12-08 | PellePharm, Inc. | Formulations topiques pour l'administration de composés inhibiteurs du hérisson et leur utilisation |
EP3316889A4 (fr) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Analogues de la cortistatine, et synthèses et leurs utilisations |
US20170231968A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
CN105622708B (zh) * | 2016-02-14 | 2017-10-10 | 山东大学 | 治疗呼吸道合胞病毒感染的化合物及其制备方法与用途 |
WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN110894209A (zh) * | 2018-09-13 | 2020-03-20 | 上海科技大学 | 一种平滑受体配体 |
CN111018791B (zh) * | 2019-12-20 | 2021-05-25 | 厦门蔚嘉制药有限公司 | 一种制备洛匹那韦新方法 |
WO2021216846A2 (fr) * | 2020-04-22 | 2021-10-28 | The Regents Of The University Of Michigan | Organoïdes cérébraux à rosette unique dérivés de cellules souches et leurs utilisations associées |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT280497B (de) | 1968-03-05 | 1970-04-10 | Chemie Linz Ag | Verfahren zur Herstellung von neuen, ungesättigten Aminosteroiden |
AT300214B (de) | 1970-04-24 | 1972-07-25 | Chemie Linz Ag | Verfahren zur Herstellung von Piperidylsteroiden |
NZ193564A (en) | 1979-05-02 | 1985-01-31 | Aruba Pty Ltd | Steroid alkaloids from solanum sodomeum and pharmaceutical compositions |
US5028422A (en) | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
US5026882A (en) | 1988-12-23 | 1991-06-25 | Smithkline Beecham Corporation | Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase |
AU654474B2 (en) * | 1990-01-18 | 1994-11-10 | Cura Nominees Pty Ltd | Glycoalkaloids |
US5639738A (en) | 1992-02-20 | 1997-06-17 | Hyal Pharmaceutical Corporation | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
JPH04230696A (ja) | 1990-12-28 | 1992-08-19 | Sanwa Shiyouyaku Kk | 新規なステロイド系化合物および制癌剤 |
AU659625B2 (en) | 1991-01-18 | 1995-05-25 | Clilco, Ltd. | Lice-repellant compositions |
US5466687A (en) | 1992-10-22 | 1995-11-14 | Dr. Karl Thomae Gmbh | Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation |
US5486511A (en) * | 1993-05-25 | 1996-01-23 | Merrell Dow Pharmaceuticals Inc. | 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase |
CN1102993A (zh) | 1993-12-21 | 1995-05-31 | 吴文才 | 多酶体系加工中草药的制剂方法 |
US6057091A (en) | 1994-12-02 | 2000-05-02 | The Johns Hopkins University School Of Medicine | Method of identifying compounds affecting hedgehog cholesterol transfer |
DE19517147C2 (de) | 1995-05-10 | 1999-07-01 | Hexal Pharmaforschung Gmbh | Aciclovir-Zubereitung |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6127366A (en) | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
JP2002503088A (ja) | 1996-10-07 | 2002-01-29 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 新規ヘッジホッグ由来ポリペプチド |
US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
TW577875B (en) | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
CA2280736C (fr) | 1997-02-10 | 2012-05-29 | The President And Fellows Of Harvard College | Procedes destines a moduler l'hematopoiese et la croissance vasculaire |
US6495532B1 (en) | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
AU7826398A (en) | 1997-06-17 | 1999-01-04 | Abbott Laboratories | Pyrrolidine carboxylic acid derivatives as endothelin antagonists |
US20050130922A1 (en) | 1997-06-20 | 2005-06-16 | Altaba Ariel R.I. | Method and compositions for inhibiting tumorigenesis |
AU7980098A (en) | 1997-06-20 | 1999-01-04 | Elena Y. Enioutina | Method to enhance innate immunity defense mechanisms by treatment with plan t-derived alkaloids |
US6238876B1 (en) | 1997-06-20 | 2001-05-29 | New York University | Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma |
US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
US5892038A (en) | 1997-12-08 | 1999-04-06 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
US6288048B1 (en) | 1998-02-13 | 2001-09-11 | The Johns Hopkins University School Of Medicine | Cholesterol and hedgehog signaling |
US6432970B2 (en) * | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
CA2326654C (fr) * | 1998-04-09 | 2010-11-09 | Johns Hopkins University School Of Medicine | Utilisation de derives steroides alcaloidiques servant d'inhibiteurs de voies de signalisation "hedgehog" |
US6867216B1 (en) | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US7098196B1 (en) | 1999-10-13 | 2006-08-29 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
ES2233383T3 (es) | 1999-06-08 | 2005-06-16 | Lorantis Limited | Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog. |
US20050080138A1 (en) | 1999-09-16 | 2005-04-14 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
AU780612C (en) | 1999-10-14 | 2005-10-20 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1646395B8 (fr) | 1999-11-30 | 2014-12-17 | Curis, Inc. | Methodes et compositions permettant de reguler l'activite des lymphocytes |
US6683108B1 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Agonists of hedgehog signaling pathways and uses related thereto |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
AU7549501A (en) | 2000-06-16 | 2002-01-02 | Biogen Inc | Angiogenesis-modulating compositions and uses |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
CU23175A1 (es) | 2000-07-17 | 2006-09-22 | Ct De Investigacion Y Desarrol | Formulacion liposomica de propionato de clobetasol |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1387674B1 (fr) | 2000-10-13 | 2017-01-18 | Curis, Inc. | Antagonistes hedgehog, procedes et utilisations associees |
EP1401469A2 (fr) | 2001-04-09 | 2004-03-31 | Lorantis Limited | Hedgehog |
CA2452152A1 (fr) | 2001-07-02 | 2002-10-10 | Sinan Tas | Utilisation de cyclopamine dans le traitement du psoriasis |
US20050011207A1 (en) | 2003-07-14 | 2005-01-20 | Porter Kevin J. | Control of air conditioning system with limited number of discrete inputs |
KR20050037103A (ko) | 2003-10-17 | 2005-04-21 | 주식회사 엘지생활건강 | 피부 미백용 화장료 조성물 |
US7390688B2 (en) | 2005-02-21 | 2008-06-24 | Casio Computer Co.,Ltd. | Semiconductor device and manufacturing method thereof |
WO2010030948A2 (fr) * | 2008-09-12 | 2010-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Signalisation hedgehog et cellules souches cancéreuses dans des malignités de cellules hématopoïétiques |
-
2000
- 2000-10-13 US US09/688,076 patent/US7098196B1/en not_active Expired - Lifetime
- 2000-10-13 AT AT00973544T patent/ATE328002T1/de not_active IP Right Cessation
- 2000-10-13 EP EP00973544A patent/EP1235851B1/fr not_active Expired - Lifetime
- 2000-10-13 IL IL14906900A patent/IL149069A0/xx active IP Right Grant
- 2000-10-13 DE DE60028411T patent/DE60028411T2/de not_active Expired - Lifetime
- 2000-10-13 AU AU12045/01A patent/AU781524B2/en not_active Expired
- 2000-10-13 JP JP2001530353A patent/JP5420128B2/ja not_active Expired - Lifetime
- 2000-10-13 WO PCT/US2000/028479 patent/WO2001027135A2/fr active Application Filing
- 2000-10-13 CA CA002386190A patent/CA2386190C/fr not_active Expired - Lifetime
- 2000-10-13 EP EP06011086A patent/EP1728797A3/fr not_active Withdrawn
-
2002
- 2002-04-10 IL IL149069A patent/IL149069A/en unknown
-
2006
- 2006-01-23 US US11/338,503 patent/US7476661B2/en not_active Expired - Lifetime
- 2006-07-03 AU AU2006202843A patent/AU2006202843B2/en not_active Expired
- 2006-12-04 IL IL179814A patent/IL179814A/en active IP Right Grant
-
2008
- 2008-03-28 US US12/079,776 patent/US7998946B2/en not_active Expired - Fee Related
-
2011
- 2011-06-16 IL IL213594A patent/IL213594A/en active IP Right Grant
- 2011-07-05 US US13/176,297 patent/US8163719B2/en not_active Expired - Fee Related
- 2011-07-25 JP JP2011162523A patent/JP2011251991A/ja active Pending
-
2012
- 2012-02-01 US US13/363,934 patent/US9440988B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL179814A0 (en) | Regulators of the hedgehog pathway,compositions and uses related thereto | |
PL312962A1 (en) | Thermally stable xylanases | |
HUP0300268A3 (en) | Herbicidal benzoylpyrazole derivatives, compositions containing the same and their use | |
HK1041723A1 (en) | Gas flow rate controller and gas appliance using the same. | |
MXPA03009234A (es) | COMPOSICIONES COSMeTICAS QUE CONTIENEN POLIMEROS DE DISPERSIoN. | |
ZA200305175B (en) | Personal wash compositions containing particle-in-oil dispersion. | |
ID30238A (id) | Komposisi-komposisi amifostin amorf yang stabil dan metode-metode untuk pembuatan dan penggunaannya | |
EP2033965A3 (fr) | Modification structurale de 17-alpha-substitué-11-bêta-substitué-4-aryle et 21-substitué 19-norpregnadienedione en tant que nouveaux agents antiprogestatifs | |
DE19847106C8 (de) | Vorrichtung zur Regelung des Fahrzeugniveaus | |
Haringsma et al. | The value of fluorescence techniques in gastrointestinal endoscopy: better than the endoscopist's eye? I: The European experience | |
Marcon et al. | The value of fluorescence techniques in gastrointestinal endoscopy-better than the endoscopist's eye? II: The North American experience | |
IL99190A0 (en) | Plant-protecting agents containing isoxazolines or isothiazolines,and novel isoxazolines and isothiazolines | |
AU2003294253A1 (en) | Emulsions including surface-modified organic molecules | |
PT1235579E (pt) | Composicoes farmaceuticas contendo trimegestona | |
MXPA05001074A (es) | Combustible emulsionado por agua/hidrocarburos, su preparacion y sus utilizaciones. | |
AU1100897A (en) | Stabilized antisun compositions | |
AU2000261384A1 (en) | Porous agglomerates containing iron and at least one further element from groups5 or 6 of the periodic table for use as an alloying agent | |
HUP9901605A3 (en) | Additive for stabilizing fuel of water content, the stabilized fuel and application thereof | |
Moayyedi et al. | Pseudomonas and endoscopy | |
WO2002020823A3 (fr) | Methodes et compositions de visualisation et d'interference avec la liaison chromosomique de molecules extrachromosomiques | |
AU7533800A (en) | Device for temperature controlled housing of a planar optical component | |
WO1999047654A3 (fr) | Association de genes pour la regulation de l'induction de la floraison chez les plantes cultivees et les plantes d'ornement | |
BR0003379A (pt) | Sistema de regulagem do deslizamento de propulsão | |
Rösch et al. | Update in Gastroenterologic Endoscopy | |
Castleman et al. | Salud ocupacional |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |